Loading clinical trials...
Loading clinical trials...
The Efficacy and Safety of Iparomlimab and Tuvonralimab (QL1706) Combined With Lenvatinib as Neoadjuvant Therapy in Renal Cancer With Partial Nephrectomy Indications But High Surgical Risk：A Single Arm, Phase II Clinical Study
Conditions
Interventions
QL1706 Combined With Lenvatinib
Locations
1
China
Sun Yat-sen University Cancer Center
Guangzhou, China
Start Date
November 21, 2025
Primary Completion Date
December 31, 2027
Completion Date
December 31, 2028
Last Updated
February 5, 2026
NCT06863311
NCT07123090
NCT07388771
NCT06349642
NCT07300241
NCT05433142
Lead Sponsor
Sun Yat-sen University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions